Articles tagged with Cancer Patients
The ECOG-ACRIN Cancer Research Group has opened a new treatment arm in the NCI-MATCH trial for patients with DNA mismatch repair deficiency and LAG-3 expression. The trial is evaluating two immunotherapy combinations: relatlimab plus nivolumab and dabrafenib plus trametinib, both targeting BRAF mutations.
A clinical trial found that genomic sequencing enabled 107 patients to receive matched therapy, increasing treatment options for those experiencing cancer relapse. The study identified previously unknown mutations and showed promise for using circulating tumor DNA to identify targetable alterations.
Researchers at Weill Cornell Medicine have found that an enzyme called ART1 can modify a receptor on tumor-fighting immune cells, triggering their death. Blocking ART1 increased the presence of these immune cells within tumors and slowed or stopped tumor growth in animal models.
A new retrospective cohort study analyzed data from over 4.5 million adult cancer patients, revealing a significantly higher risk of cardiovascular mortality and events following a new cancer diagnosis. The study highlights the need for a collaborative approach to healthcare for cancer patients and survivors.
Two clinical trials will report groundbreaking data on adjuvant olaparib for germline BRCA1/2 associated breast cancer and pembrolizumab for early-stage non-small cell lung cancer. These treatments aim to improve survival rates and reduce recurrence.
The Southeastern Consortium for Lung Cancer Health Equity aims to address disparities in lung cancer screening among racially and ethnically diverse populations. Researchers will develop more precise methods for identifying those at highest risk of lung cancer diagnoses.
A study of insurance claims data found that state laws governing opioid prescribing had a negligible effect on opioid prescribing trends. The authors suggest that shifting clinical guidelines, professional norms, or other factors may be driving the decline in opioid prescribing. In contrast, a post-hoc analysis of an ASPREE trial found...
Research found a significant drop in new cancer diagnoses during the COVID-19 pandemic, particularly for screening cancers like breast, cervical, and colorectal cancer. The study estimates around 12,600 cancers went undetected between March 2020 and September 2020.
A comprehensive review of over 60 studies confirms that COVID vaccination is around 80% effective in protecting people with cancer against SARS-CoV-2 infection. The mRNA vaccines were found to be the most effective, and multiple vaccinations are recommended for better protection.
Researchers found that hydroxychloroquine inhibits pathways that drive resistance to cisplatin in head and neck cancers, restoring tumor-killing effects. The study paves the way for a clinical trial combining hydroxychloroquine and cisplatin to treat chemotherapy-resistant patients.
A Moffitt study found that COVID-19 vaccination led to seroconversion in most cancer patients, but with differing antibody response rates among various cancer types and treatments. Patients with blood cancers had lower seroconversion rates compared to those with solid tumors, highlighting the need for personalized immune responses.
A CHOP-led study found bortezomib significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma. The trial also showed that intensifying the chemotherapy regimen allowed for elimination of radiation in nearly all patients, resulting in excellent outcomes.
A new study found that dual-eligible patients for Medicare and Medicaid have poorer outcomes and higher costs after cancer surgery, even in high-quality hospitals. These patients are more likely to experience complications, longer hospital stays, and lower chances of going home instead of a nursing facility.
Researchers at the University of South Australia have developed a new way to deliver chemotherapy drugs, using liposomal formulations that target tumors more effectively. This breakthrough could improve treatment outcomes for thousands of cancer patients, reducing side effects and improving quality of life.
A study led by University of Illinois Chicago researchers found that structural racism can result in poorer leukemia outcomes for Black and Hispanic patients. Neighborhood disadvantage was a significant predictor of leukemia-specific death, accounting for nearly all the Black-white disparity in AML-related death.
A U-M study defines how a cytokine and fatty acid combination triggers ferroptosis, a type of cell death previously studied with synthetic molecules. This natural mechanism could make immunotherapy treatments more effective, particularly for cancers where the treatments currently work for only about 30% of patients.
A new fluorescent DNA label has been developed to visualize disrupted DNA architecture in cancer cells, with promising results for improved cancer diagnoses and risk stratification. The study showed that the label can distinguish normal tissue from precancerous and cancerous lesions.
A study of nearly 40,000 Medicare beneficiaries found racial disparities in the use of MRI among Black and white patients with new prostate cancer diagnoses. The study identified factors such as insurance coverage, socioeconomic status, and geographic location that contribute to these disparities.
The Cancer Prevention & Research Institute of Texas has awarded a grant extension to Dr. Rakhshanda Rahman, allowing her to provide no-cost mammograms and Pap smears to underinsured and uninsured women in the Permian Basin. The program aims to address high cervical cancer incidence and mortality rates in West Texas.
Researchers at Johns Hopkins Medicine discovered 110 genes, circular RNAs, lipids and metabolites that differ between medulloblastoma patients' cerebrospinal fluid and healthy controls. These findings provide proof of principle for novel biomarkers to detect and track the disease.
Scientists have discovered a new therapeutic approach to aid the immune system in fighting cancer, offering hope for better solutions for patients. Researchers found that blocking the EP4 molecule can 'free' the immune system and restore its cancer-fighting functions.
Computer simulations reveal metformin's effectiveness in targeting diabetes and some cancers, but also its negative consequences for others. Researchers emphasize the need for precision medicine to individualize treatment based on patient profiles.
A University of Cincinnati clinical trial showed promising results for patients with intermediate risk head and neck cancer when an immunotherapy drug, pembrolizumab, was added to standard treatment regimens. The study found improved one-year disease-free survival rates compared to historical controls.
A new study found that traditional Chinese medicine Shengmai Yin increases the sensitivity of cancer cells to radiation, reducing radioresistance. By altering DNA methylation status, SMY enhances the efficacy of radiation therapy and reduces side effects.
A new phase II trial found that mid-treatment PET scans can help determine if patients with p16-positive oropharynx cancer can receive a lower dose of radiation therapy without compromising cancer control. The study reported fewer short-term side effects in patients who received de-escalated therapy.
Researchers at UVA Cancer Center have made a groundbreaking discovery about the EP300 gene and its role in small-cell lung cancer. The study found that the gene makes a protein with properties that can both foster and prevent tumor formation, providing a new potential target for treatment.
A systematic review found that intersectional identities are associated with lower diagnostic screening and reception of preventative services. Patients with these identities face increased distrust of the healthcare system and negative cancer outcomes.
A new AI model combines multiple machine learning methods to accurately detect thyroid cancer and predict treatment outcomes from routine ultrasound images. The multimodal platform achieved high accuracy rates in detecting malignancies and predicting pathological stage and genomic mutations.
A blood test detecting circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. The biomarker test may detect recurrent disease earlier than imaging or other standard methods, allowing physicians to personalize treatment more quickly for patients whose cancer returns.
A new synthetic substance, PECS-101, has been shown to prevent neuropathic pain caused by chemotherapy while improving cancer treatment outcomes. The study, conducted in mice, found that PECS-101 had no adverse effects and did not cause dependence.
Researchers investigated COVID-19 mortality in adult cancer patients, finding that systemic treatments and comorbidities played a role in increased risk. The study analyzed 2,500 patients and identified specific tumor subtypes associated with higher mortality rates.
Scientists have developed a new therapy called CINDELA, which employs CRISPR-Cas9 to kill cancer cells while leaving normal tissues intact. The treatment targets specific mutations found in cancer cells and induces cell death through DNA double-strand breaks.
New study reveals that T-cell responses against the SARS-CoV-2 spike protein can predict protection against infection. In healthy individuals, T cells with a specific cytokine profile offered immunity against COVID-19. In contrast, cancer patients showed lower T-cell responses and increased susceptibility to infection.
Scientists have discovered a new subtype of relapsed pediatric AML characterized by a specific gene mutation called UBTF exon 13 tandem duplication (UBTF-TD), which is associated with poor outcomes and an increased incidence of minimal residual disease. This mutation can be used to identify high-risk patients and guide treatment.
A team of researchers has discovered blood biomarkers that can predict patient response to immunotherapy treatment for melanoma. The study found that patients with increased lactate levels and specific lipid and amino acid metabolites were more likely to respond to treatment.
A recent study published in JAMA Network Open found that the COVID-19 pandemic led to fewer early-stage and more late-stage breast cancer diagnoses. Researchers at UC San Diego Health surveyed patients with breast and colorectal cancers in 2019 and 2020, finding a significant increase in stage IV diagnoses.
Researchers from National Cancer Centre Singapore have found a potential new strategy to treat peritoneal carcinomatosis, a metastatic form of intra-abdominal cancer. The team identified targeting ascites, excess fluid in the abdomen, as a way to remove fuel that drives cancer growth.
Results from the Phase III EMPOWER trial demonstrate the efficacy of PD-1 inhibitor cemiplimab in improving overall survival for women with recurrent and/or metastatic cervical cancer. The study showed a 31% lower risk of death in patients receiving cemiplimab compared to chemotherapy.
The COXEN GC score was a significant predictor of overall survival when looking at both treatment groups combined. The study found no association between COXEN scores and progression-free survival, but the biomarker may serve as a potential tool to improve patient outcomes.
A comprehensive analysis of over 2,200 patients in Europe reveals the complexity of cholangiocarcinoma, a rare cancer often diagnosed at an advanced stage. The study highlights the need for education programs to raise awareness and improve early diagnosis, survival, and quality of life.
A new study found that cancer patients currently undergoing treatment are more likely to believe false information about COVID-19, while those no longer in treatment are less vulnerable. This is due to heightened anxiety and increased information seeking, which can impact their critical thinking abilities.
A study by researchers at the University of Illinois found that oncology dietitians rarely ask cancer patients about food insecurity, despite awareness that many experience it. The dietitians' estimates of prevalence varied widely, and most did not use validated tools to screen for food insecurity.
Patients with severe coronary artery calcium have a significantly increased risk of major adverse cardiovascular events during thoracic radiation therapy for non-small cell lung cancer. The study found that patients with severe coronary artery calcium had a 21.4 times increased risk compared to those with no coronary artery calcium.
Paczesny will explore biomarkers and a new type of immune cell to identify and regulate acute lung injury after BMT. She aims to improve understanding of signaling mechanisms in lung injury after BMT, particularly as they relate to idiopathic pneumonia syndrome.
A novel immune-profiling method can return detailed immune cell type proportions using only DNA from blood, potentially allowing for individualized prediction of outcomes in immunotherapy patients. This approach offers the opportunity to ask and answer questions about the immune system in health and disease.
Researchers have developed a new therapeutic approach to block mutated RAS proteins, which are frequently found in cancers. The method, using small molecules, has the potential to work with multiple mutant forms of RAS in various types of cancers, including pancreatic, lung, and colorectal cancers.
A study found that lung cancer patients coped better with the pandemic, showing lower levels of anxiety and depression compared to healthy individuals. The strength needed to face their disease helped them cope more effectively with COVID-19 fears.
A study by MedUni Vienna found that many cancer patients can build up sufficient immunity against SARS-CoV-2 after the third vaccination. However, patients with blood cancers may not develop protection due to immunosuppressive treatments.
Researchers developed a new personalized test for monitoring cancer recurrence in acute lymphoblastic leukemia (ALL) patients. The MP PCR uses multiple genomic markers to detect disease recurrence sooner, improving treatment strategies and patient stratification.
A culturally tailored patient navigation program improved the rate of colorectal cancer screening among Hispanic adults, reducing historical gender disparities. The program's colonoscopy completion rate was 85%, with no difference between males and females.
A new symptom management approach, WRITE Symptoms, guides patients to reflect on their symptoms and develop strategies for addressing target symptoms. Both nurse-led and self-directed versions of the tool improved women's sense of control over their symptoms after eight weeks.
A new study found nearly 17% of cancer survivors experience moderate or increased housing insecurity, complicating disease management and healthcare navigation. Housing insecurity also correlates with lower household income, educational attainment, and being Black.
Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.
The NRG-GOG 0281/LOGS trial demonstrated that trametinib significantly reduces disease progression and improves response rates in women with recurrent low-grade serous carcinoma of the ovary/peritoneum. The study found a trend towards higher overall survival rates when compared to standard of care options.
Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.
The ACC cardiooncology course is designed to educate clinicians on improving awareness, identification, monitoring, and management of cardiovascular diseases in cancer patients. The course aims to help clinicians minimize cardiotoxicity from cancer therapies, leading to improved overall survival and quality of life for oncology patients.
The ESMO-WHO collaboration developed an evidence-based methodology for evaluating national medication formularies, helping Kazakhstan update its list of essential cancer medicines and treatment protocols. The approach resulted in increased budget allocation to cancer care and improved access to high-quality treatments.
A new study from Regenstrief Institute identifies divergent priorities among cancer patients and their caregivers during active treatment, with patients focusing on physical issues like pain and caregivers prioritizing social support. The research emphasizes the need for enhanced whole-family approaches to supportive oncology care deli...
A moderate exercise programme was shown to improve chemotherapy success rates and reduce negative side effects in oesophageal cancer patients. The study found that exercise can be safely included as part of cancer treatment, potentially benefiting more patients.
Scientists at University College London have developed a novel cancer therapy using magnetic seeds guided by an MRI scanner to heat and destroy tumours. The therapy, called MINIMA, has the potential to precisely treat hard-to-reach cancers with minimal side effects.